A seminal, annual meeting updating advisers on next season’s influenza vaccines was abruptly canceled by the Food and Drug Administration. The FDA’s Vaccines and Related Biological Products Advisory Committee was slated to meet on March 13,

Epidemiologist Michael Osterholm, the head of the University of Minnesota Center for Infectious Disease Research and Policy, joined Morning Edition host Cathy Wurzer to talk about the implications of axing the meeting.